Key facts
- It has raised $18.6M across 3 recorded rounds; the latest was Early Stage VC ($7.3M) in Dec 2024.
- Orcosa has filed 4 Form Ds with the SEC since 2021, most recently Jan 2025 ($11.3M sold to 36 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Orcosa
Funding rounds
3 roundsAbout Orcosa
Operator of a life sciences company intended to modernize drug delivery technology and improve patient outcomes through its proprietary therapeutic delivery technology. The company's therapeutic delivery technology is an easy-to-take orally disintegrating tablet platform engineered to enhance drug absorption, enabling medical professionals to treat moderate to severe pain and provide a safe alternative treatment option to opioids.
- Sector
- Healthcare
- HQ
- Ewing, NJ, United States
- Founded
- 2020
- Employees
- 12
- Website
- orcosa.com/
- Ownership
- Privately Held (backing)
Orcosa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orcosa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orcosa in its N-PORT filings yet. We sweep new filings monthly.